Physician

Adan Gonzalez, MD

According to 2025 Medicare claims, Adan Gonzalez, MD (NPI: 1528249745) practices nephrology in the Amarillo, TX market, with the plurality of this provider's patient population coming from Potter, TX. This provider's primary affiliated billing organization is AMARILLO NEPHROLOGY ASSOCIATES, P.A. (NPI: 1861507964; TIN: 752684668) and primary practice location at 79124-2166. Gonzalez is affiliated with the Texoma Clinical Partners ACO, LLC (ACO ID: A4585), Caravan Health ACO 43 LLC (ACO ID: A4974), Main Street Rural Health Magnolia ACO LLC (ACO ID: A5400), Main Street Rural Health Sycamore ACO LLC (ACO ID: A5403), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Gonzalez's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 539 traditional Medicare patients, billed 2,131 HCPCS/CPT codes, and received $241,224 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 2,276 prescription claims across 406 beneficiaries totaling $1,066,906 in drug costs, led by Farxiga (Dapagliflozin Propanediol). 2021 DME data shows 30 claims. Open Payments data shows 51 records totaling $1,147. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $397,829 and ending at $1,066,906. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	693	3,648	$342,286
2016	693	3,355	$327,470
2017	727	3,300	$322,857
2018	716	3,361	$357,917
2019	699	3,226	$356,743
2020	668	3,017	$333,955
2021	579	2,323	$307,022
2022	547	2,248	$287,023
2023	528	2,275	$266,377
2024	539	2,131	$241,224

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	391	2,425	$397,829
2016	400	2,592	$417,317
2017	430	2,741	$642,542
2018	421	2,820	$576,347
2019	427	2,670	$394,386
2020	398	2,525	$270,049
2021	384	2,066	$297,141
2022	337	1,706	$336,982
2023	359	1,872	$591,975
2024	406	2,276	$1,066,906

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	255	$42,676
2016	N/R	305	$27,102
2017	11	317	$28,602
2018	N/R	260	$20,345
2019	N/R	305	$24,275
2020	N/R	260	$19,993
2021	N/R	30	$845
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	117	397	$267
90961	Dialysis services, 2-3 physician visits per month (20 years or older)	69	120	$222
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	74	87	$95
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	217	494	$66
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	183	682	$59

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	259	15,284	$282,212
Velphoro	Sucroferric Oxyhydroxide	48	1,860	$157,796
Xphozah	Tenapanor Hcl	46	1,620	$153,895
Kerendia	Finerenone	66	3,450	$72,488
Entresto	Sacubitril/Valsartan	50	3,180	$70,342

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	51	$1,147	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adan Gonzalez, MD?

Tedicare shows public-source Medicare data for Adan Gonzalez, MD (NPI 1528249745), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adan Gonzalez, MD have ACO affiliation data?

Adan Gonzalez, MD is shown with ACO affiliation data for Texoma Clinical Partners ACO, LLC (MSSP, ACO ID A4585), Caravan Health ACO 43 LLC (MSSP, ACO ID A4974), Main Street Rural Health Magnolia ACO LLC (MSSP, ACO ID A5400), Main Street Rural Health Sycamore ACO LLC (MSSP, ACO ID A5403), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Adan Gonzalez, MD?

Adan Gonzalez, MD is linked to AMARILLO NEPHROLOGY ASSOCIATES, P.A. (billing NPI 1861507964) in the available physician profile data.

Does Adan Gonzalez, MD have Open Payments data?

Adan Gonzalez, MD has 51 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.